Technology, pharmacology, and clinical outcomes of sirolimus coated balloons for peripheral arterial interventions
Related Experiment Video
Updated: Jan 15, 2026

Author Spotlight: Utilizing Venoplasty Balloon Model in Rodents to Simulate Surgical Interventions for Deep Veins
Published on: May 24, 2024
Ruttiros Khonkarn1,2, Pranvera Ramadani3, Sheng Qi4
1Department of Pharmaceutical Science, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand.
Introduction:
Peripheral arterial intervention is a rapidly evolving field with a significant impact on an aging population.
Areas Covered:
Treatment concepts evolve rapidly, with new therapies providing sustainable and cost-effective solutions for complex patients.
Expert Opinion:
Metal stenting has been replaced by the 'leave-nothing-behind' approach, and plain balloon angioplasty devices have been replaced by drug-coated balloons (DCBs). While paclitaxel was initially used, sirolimus has more recently shown promising outcomes. This review article provides an overview of the technology and pharmacology behind sirolimus-coated balloons (SRL-DCB) and presents existing clinical evidence of their use.
More Related Videos
04:30A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
Related Concept Videos
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease V: Postoperative Nursing Management
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...